Cerus (CERS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting commenced virtually with board and leadership introductions and confirmation of the agenda.
Inspector of Election and independent auditors were introduced, and meeting procedures were outlined.
Notice of meeting and quorum were confirmed, allowing business to proceed.
Board and executive committee updates
Vivek Jayaraman will succeed the current CEO as President and CEO effective July 1st.
Shareholder proposals
Four proposals were presented: election of two directors, amendment of the 2024 Equity Incentive Plan, advisory approval of executive compensation, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cerus
- Q1 2026 revenue up 23%, product revenue up 24%, and net loss narrowed to $1.6 million.CERS
Q1 20263 May 2026 - Record revenue growth and global expansion driven by INTERCEPT blood safety technologies.CERSCorporate presentation22 Apr 2026
- Proxy covers director elections, equity plan expansion, pay, auditor, and governance highlights.CERSProxy filing22 Apr 2026
- Virtual vote set for June 2026 on directors, equity plan, pay, and auditor ratification.CERSProxy filing22 Apr 2026
- Record 2025 growth and global expansion highlight strong momentum in blood safety innovation.CERSCorporate presentation9 Mar 2026
- Double-digit growth driven by U.S. and global expansion, new products, and strong partnerships.CERSTD Cowen 46th Annual Health Care Conference3 Mar 2026
- 2025 revenue hit $233.8M with narrowing losses and strong IFC and INT200-driven growth.CERSQ4 20252 Mar 2026
- Q2 product revenue up 16%, net loss narrowed, and 2024 guidance raised to $175–178M.CERSQ2 20242 Feb 2026
- BARDA awards up to $248M for U.S. program; Europe plans new submission after CE Mark setback.CERSStudy Update19 Jan 2026